Botanix Pharmaceuticals Limited (BOT) is a dermatology company with operations in both Philadelphia and Phoenix. The company is currently advancing its lead product, Sofdra, which is aimed at treating primary axillary hyperhidrosis. This condition, characterised by excessive underarm sweating, can significantly impact the quality of life for those affected. Botanix is working diligently to navigate the complex process of FDA approval for Sofdra, with the goal of making this innovative treatment available to patients who need it.